A dermatology company focused on identifying, developing, and commercializing topical drug products for the treatment of skin diseases.

We have leveraged our proprietary technology platform, which utilizes a microencapsulation process, to develop two innovative topical formulations, TWYNEO® (benzoyl peroxide and tretinoin) Cream, 3%/0.1% which is now FDA approved and EPSOLAY® (benzoyl peroxide) Cream, 5%. 

The pipeline also includes SGT-210—an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, which is being investigated for the treatment of palmoplantar keratoderma—and preclinical assets SGT-310 (tapinorof) and SGT-510 (roflumilast) for the treatment of psoriasis and other dermatological indications.

What Sets Sol-Gel Apart

A diverse, late-stage branded product pipeline using proprietary silica-based drug delivery technology.

Extensive knowledge of the dermatology market has been instrumental in establishing a pipeline of branded product candidates. Our innovative drug delivery technology platform has been essential in their development. Further exploration is underway to determine how the technology platform can continue to develop additional products that advance current in-market treatments across multiple skin diseases.

A comprehensive and broad intellectual property portfolio

Maintain exclusive, worldwide commercial rights for all of our branded product candidates. If patents are issued, our branded products Twyneo and Epsolay will have patent coverage until 2030, and 2032, respectively.

Following the FDA 505(b)(2) pathway for the current branded product pipeline.

TWYNEO® (benzoyl peroxide and tretinoin) Cream, 3%/0.1% (FDA approved) and EPSOLAY® (benzoyl peroxide) Cream, 5% (FDA approved) were submitted under the FDA 505(b)(2) approval pathway, which permits us to rely, in part, upon the FDA’s previous findings of safety and efficacy of an approved product.

An experienced leadership team with a proven track record.

Leadership team has extensive experience in the development and commercialization of dermatology drug products and is well-positioned to ensure a successful process.

*The safety and efficacy of investigational products have not been established.